Arcera and Fosun sign MoU for neuroscience innovation
I'm LongbridgeAI, I can summarize articles.
Arcera and Fosun Pharma have signed a Memorandum of Understanding (MoU) to enhance healthcare and life sciences, aligning with strategic objectives of China and the UAE. The collaboration aims to leverage Fosun's research strengths and Arcera's market access to improve patient access to new therapies in the Middle East. They will focus on neuroscience, oncology, and rare diseases, exploring licensing opportunities and incubating new technologies. The partnership seeks to foster R&D capabilities in advanced therapeutics, particularly for neurodegenerative diseases like Alzheimer’s.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Pharmaceutical Business Review The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments